The Impact of FDA’s Draft Guidance for Oncology Patient-Reported Outcomes Date Published: Sep 10, 2021 Whitepaper Signant’s in-house experts discuss the key takeaways from the FDA’s recent PRO guidance, including the recommended measures and frequency in administration. Readers will also learn the core domains that the agency values the most when reviewing oncology PROM data. Download Now Share: LinkedIn0Tweet0 Recommended Resources Article Five Considerations for BYOD Studies Bill Byrom, Principal, eCOA Science In our drive to make trial participation simpler, a bring-your-own-device (BYOD) model is thought to be a convenient approach for trial participants to... Download Now Oncology Solutions Overview Download Now Brochure Decentralized Clinical Trial Solutions Download Now Brochure